You are here

  • Home
  • Archive
  • Volume 65, Issue Suppl 1
  • OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1

Article metrics

Article menu
Download PDFPDF
BSG 2016
OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1

 

Online download statistics by month:

Online download statistics by month: August 2016 to March 2024

AbstractFullPdf
Aug 20161100
Sep 20163001
Oct 20163505
Nov 20163305
Dec 20163702
Jan 20174406
Feb 20171901
Mar 2017401
Apr 2017701
May 20172301
Jun 20172301
Jul 20172402
Aug 20172002
Sep 20173602
Oct 20172600
Nov 20171000
Dec 20171201
Jan 20182400
Feb 20181201
Mar 20181000
Apr 20182200
May 20184802
Jun 20183202
Jul 20181600
Aug 2018802
Sep 20181801
Oct 20181002
Nov 20181200
Dec 2018600
Jan 2019700
Feb 2019601
Mar 2019501
Apr 20191101
May 2019100
Jun 2019701
Jul 2019600
Aug 20191001
Sep 2019400
Oct 20192002
Nov 2019200
Dec 2019801
Jan 2020200
Feb 2020601
Mar 2020400
Apr 2020401
Jun 2020500
Jul 2020400
Aug 20201400
Sep 20204101
Oct 20201302
Nov 2020600
Dec 2020800
Jan 20211802
Feb 2021600
Mar 2021700
Apr 2021200
May 2021301
Sep 2021103
Oct 2021100
Nov 2021600
Dec 2021600
Jan 20223300
Feb 20221300
Mar 20221200
Apr 20221100
May 20221100
Jun 2022600
Jul 20227901
Aug 20221200
Sep 20222200
Oct 20221003
Nov 2022600
Dec 20223400
Jan 2023400
Feb 2023200
Mar 20231401
Apr 20234300
May 2023800
Jul 20237000
Aug 2023800
Sep 20231200
Oct 2023400
Nov 20238405
Dec 2023800
Jan 2024200
Feb 20242401
Mar 2024400
Total1392071